Obesity, hormone therapy, estrogen metabolism and risk of postmenopausal breast cancer

Francesmary Modugno, Kevin E. Kip, Barbara Cochrane, Lewis Kuller, Thomas L. Klug, Thomas E. Rohan, Rowan T. Chlebowski, Norman Lasser, Marcia L. Stefanick

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Hormone therapy (HT) and body mass index (BMI) have been associated with postmenopausal breast cancer. Because estrogen metabolism may affect breast cancer risk and can be altered by weight and HT, it might play a role in the HT-BMI-breast cancer associations. We undertook a nested case-control study within the Observational Study of the Women's Health Initiative. Baseline levels of 2- and 16α-hydroxy estrone (2-OHE1 and 16α-OHE1) were measured in 200 women who developed breast cancer during follow-up and 200 healthy controls matched to cases by ethnicity, enrollment date, clinic site, type of HT and years since menopause. Wilcoxon nonparametric tests were used to compare estrogen metabolite levels between cases and controls. Conditional logistic regression was used to assess the relationship between BMI, estrogen metabolites and breast cancer risk. 16α-OHE1 levels were modestly but significantly higher in HT users among cases (median 356 pg/ml vs. 315 pg/ml) and controls (354 pg/ml vs. 298 pg/ml). 2-OHE1 levels were substantially and significantly higher in HT users among cases (369 pg/ml vs. 125 pg/ml) and controls (347 pg/ml vs. 134 pg/ml). For non-HT users only, greater BMI and higher 16α-OHE1 levels were individually and jointly associated with increased breast cancer risk (OR for women with high BMI and high 16α-OHE1 compared to those with low BMI and low 16α-OHE1 = 3.51, 95% CI = 1.34-9.16). No associations between BMI, estrogen metabolism and breast cancer risk were found for HT users. Estrogen metabolism differs according to both BMI and HT use, potentially explaining the interaction between BMI and HT in relation to breast cancer risk.

Original languageEnglish (US)
Pages (from-to)1292-1301
Number of pages10
JournalInternational Journal of Cancer
Volume118
Issue number5
DOIs
StatePublished - Mar 1 2006

Fingerprint

Estrogens
Obesity
Body Mass Index
Hormones
Breast Neoplasms
Therapeutics
Estrone
Women's Health
Menopause
Observational Studies
Case-Control Studies
Logistic Models
Weights and Measures

Keywords

  • Body mass index
  • Breast neoplasms
  • Estrogen metabolism
  • Hormone therapy
  • Obesity

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Modugno, F., Kip, K. E., Cochrane, B., Kuller, L., Klug, T. L., Rohan, T. E., ... Stefanick, M. L. (2006). Obesity, hormone therapy, estrogen metabolism and risk of postmenopausal breast cancer. International Journal of Cancer, 118(5), 1292-1301. https://doi.org/10.1002/ijc.21487

Obesity, hormone therapy, estrogen metabolism and risk of postmenopausal breast cancer. / Modugno, Francesmary; Kip, Kevin E.; Cochrane, Barbara; Kuller, Lewis; Klug, Thomas L.; Rohan, Thomas E.; Chlebowski, Rowan T.; Lasser, Norman; Stefanick, Marcia L.

In: International Journal of Cancer, Vol. 118, No. 5, 01.03.2006, p. 1292-1301.

Research output: Contribution to journalArticle

Modugno, F, Kip, KE, Cochrane, B, Kuller, L, Klug, TL, Rohan, TE, Chlebowski, RT, Lasser, N & Stefanick, ML 2006, 'Obesity, hormone therapy, estrogen metabolism and risk of postmenopausal breast cancer', International Journal of Cancer, vol. 118, no. 5, pp. 1292-1301. https://doi.org/10.1002/ijc.21487
Modugno, Francesmary ; Kip, Kevin E. ; Cochrane, Barbara ; Kuller, Lewis ; Klug, Thomas L. ; Rohan, Thomas E. ; Chlebowski, Rowan T. ; Lasser, Norman ; Stefanick, Marcia L. / Obesity, hormone therapy, estrogen metabolism and risk of postmenopausal breast cancer. In: International Journal of Cancer. 2006 ; Vol. 118, No. 5. pp. 1292-1301.
@article{8c1ca76679e2463dad0b698fdcbad24b,
title = "Obesity, hormone therapy, estrogen metabolism and risk of postmenopausal breast cancer",
abstract = "Hormone therapy (HT) and body mass index (BMI) have been associated with postmenopausal breast cancer. Because estrogen metabolism may affect breast cancer risk and can be altered by weight and HT, it might play a role in the HT-BMI-breast cancer associations. We undertook a nested case-control study within the Observational Study of the Women's Health Initiative. Baseline levels of 2- and 16α-hydroxy estrone (2-OHE1 and 16α-OHE1) were measured in 200 women who developed breast cancer during follow-up and 200 healthy controls matched to cases by ethnicity, enrollment date, clinic site, type of HT and years since menopause. Wilcoxon nonparametric tests were used to compare estrogen metabolite levels between cases and controls. Conditional logistic regression was used to assess the relationship between BMI, estrogen metabolites and breast cancer risk. 16α-OHE1 levels were modestly but significantly higher in HT users among cases (median 356 pg/ml vs. 315 pg/ml) and controls (354 pg/ml vs. 298 pg/ml). 2-OHE1 levels were substantially and significantly higher in HT users among cases (369 pg/ml vs. 125 pg/ml) and controls (347 pg/ml vs. 134 pg/ml). For non-HT users only, greater BMI and higher 16α-OHE1 levels were individually and jointly associated with increased breast cancer risk (OR for women with high BMI and high 16α-OHE1 compared to those with low BMI and low 16α-OHE1 = 3.51, 95{\%} CI = 1.34-9.16). No associations between BMI, estrogen metabolism and breast cancer risk were found for HT users. Estrogen metabolism differs according to both BMI and HT use, potentially explaining the interaction between BMI and HT in relation to breast cancer risk.",
keywords = "Body mass index, Breast neoplasms, Estrogen metabolism, Hormone therapy, Obesity",
author = "Francesmary Modugno and Kip, {Kevin E.} and Barbara Cochrane and Lewis Kuller and Klug, {Thomas L.} and Rohan, {Thomas E.} and Chlebowski, {Rowan T.} and Norman Lasser and Stefanick, {Marcia L.}",
year = "2006",
month = "3",
day = "1",
doi = "10.1002/ijc.21487",
language = "English (US)",
volume = "118",
pages = "1292--1301",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Obesity, hormone therapy, estrogen metabolism and risk of postmenopausal breast cancer

AU - Modugno, Francesmary

AU - Kip, Kevin E.

AU - Cochrane, Barbara

AU - Kuller, Lewis

AU - Klug, Thomas L.

AU - Rohan, Thomas E.

AU - Chlebowski, Rowan T.

AU - Lasser, Norman

AU - Stefanick, Marcia L.

PY - 2006/3/1

Y1 - 2006/3/1

N2 - Hormone therapy (HT) and body mass index (BMI) have been associated with postmenopausal breast cancer. Because estrogen metabolism may affect breast cancer risk and can be altered by weight and HT, it might play a role in the HT-BMI-breast cancer associations. We undertook a nested case-control study within the Observational Study of the Women's Health Initiative. Baseline levels of 2- and 16α-hydroxy estrone (2-OHE1 and 16α-OHE1) were measured in 200 women who developed breast cancer during follow-up and 200 healthy controls matched to cases by ethnicity, enrollment date, clinic site, type of HT and years since menopause. Wilcoxon nonparametric tests were used to compare estrogen metabolite levels between cases and controls. Conditional logistic regression was used to assess the relationship between BMI, estrogen metabolites and breast cancer risk. 16α-OHE1 levels were modestly but significantly higher in HT users among cases (median 356 pg/ml vs. 315 pg/ml) and controls (354 pg/ml vs. 298 pg/ml). 2-OHE1 levels were substantially and significantly higher in HT users among cases (369 pg/ml vs. 125 pg/ml) and controls (347 pg/ml vs. 134 pg/ml). For non-HT users only, greater BMI and higher 16α-OHE1 levels were individually and jointly associated with increased breast cancer risk (OR for women with high BMI and high 16α-OHE1 compared to those with low BMI and low 16α-OHE1 = 3.51, 95% CI = 1.34-9.16). No associations between BMI, estrogen metabolism and breast cancer risk were found for HT users. Estrogen metabolism differs according to both BMI and HT use, potentially explaining the interaction between BMI and HT in relation to breast cancer risk.

AB - Hormone therapy (HT) and body mass index (BMI) have been associated with postmenopausal breast cancer. Because estrogen metabolism may affect breast cancer risk and can be altered by weight and HT, it might play a role in the HT-BMI-breast cancer associations. We undertook a nested case-control study within the Observational Study of the Women's Health Initiative. Baseline levels of 2- and 16α-hydroxy estrone (2-OHE1 and 16α-OHE1) were measured in 200 women who developed breast cancer during follow-up and 200 healthy controls matched to cases by ethnicity, enrollment date, clinic site, type of HT and years since menopause. Wilcoxon nonparametric tests were used to compare estrogen metabolite levels between cases and controls. Conditional logistic regression was used to assess the relationship between BMI, estrogen metabolites and breast cancer risk. 16α-OHE1 levels were modestly but significantly higher in HT users among cases (median 356 pg/ml vs. 315 pg/ml) and controls (354 pg/ml vs. 298 pg/ml). 2-OHE1 levels were substantially and significantly higher in HT users among cases (369 pg/ml vs. 125 pg/ml) and controls (347 pg/ml vs. 134 pg/ml). For non-HT users only, greater BMI and higher 16α-OHE1 levels were individually and jointly associated with increased breast cancer risk (OR for women with high BMI and high 16α-OHE1 compared to those with low BMI and low 16α-OHE1 = 3.51, 95% CI = 1.34-9.16). No associations between BMI, estrogen metabolism and breast cancer risk were found for HT users. Estrogen metabolism differs according to both BMI and HT use, potentially explaining the interaction between BMI and HT in relation to breast cancer risk.

KW - Body mass index

KW - Breast neoplasms

KW - Estrogen metabolism

KW - Hormone therapy

KW - Obesity

UR - http://www.scopus.com/inward/record.url?scp=31844453703&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31844453703&partnerID=8YFLogxK

U2 - 10.1002/ijc.21487

DO - 10.1002/ijc.21487

M3 - Article

C2 - 16161054

AN - SCOPUS:31844453703

VL - 118

SP - 1292

EP - 1301

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 5

ER -